论文部分内容阅读
目的:观察低剂量吉西他滨每周疗法的效果及安全性。方法:84例非小细胞肺癌(NSCLC)患者随机分为2组,每组42例。常规治疗(常规组)采用吉西他滨1200mg/m2,静脉滴注,第1、8、15天给药;低剂量每周疗法(试验组)采用吉西他滨600mg/m2,静脉滴注,第1、8、15、22天给药。2组均28d为1个疗程,连续至少2个疗程。第2疗程末评价疗效和不良反应。结果:化疗有效率常规组23.8%(10/42),试验组28.6%(12/42),组间差异无统计学意义(P>0.05)。不良反应多数为Ⅰ～Ⅱ级轻度反应,血WBC计数下降、Hb含量下降、恶心呕吐、食欲不振、肝功损害(ALT升高)等不良反应发生率试验组低于常规组,差异有统计学意义(P<0.05);PLT计数下降、肾功能损害(BUN升高)、皮肤反应以及水肿等不良反应发生率组间差异无统计学意义(P>0.05)。结论:低剂量吉西他滨每周疗法是治疗NSCLC安全有效的方法。
Objective: To observe the efficacy and safety of low-dose gemcitabine weekly therapy. Methods: Eighty-four patients with non-small cell lung cancer (NSCLC) were randomly divided into 2 groups, 42 in each group. Conventional treatment (conventional group) received gemcitabine 1200mg/m2, intravenous drip, on the 1st, 8th, and 15th days; low-dose weekly therapy (test group) received gemcitabine 600mg/m2, intravenous drip, 1st, 8th, 15 and 22 days dosing. Both groups were 28d for a course of treatment, continuous for at least 2 courses. At the end of the second treatment, efficacy and adverse reactions were evaluated. Results: The effective rate of chemotherapy was 23.8% (10/42) in the conventional group and 28.6% (12/42) in the experimental group. There was no significant difference between the two groups (P>0.05). Most adverse reactions were grade I to grade II mild reactions. The incidence of adverse reactions such as decreased blood WBC counts, decreased Hb levels, nausea and vomiting, loss of appetite, and liver function impairment (ALT elevation) were lower in the experimental group than in the conventional group. Significance (P<0.05); There was no significant difference in the incidence of adverse reactions such as decreased PLT count, impaired renal function (increased BUN), skin reaction, and edema (P>0.05). Conclusion: Low-dose gemcitabine weekly therapy is a safe and effective treatment for NSCLC.